Vanguard FTSE All-World ex-US ETF

Most Recent

  • uploads///Portfolio Composition of International Mutual Funds
    Company & Industry Overviews

    Is It Time to Invest in International Funds?

    2016 has mostly been about macro trends, thus presenting a different set of challenges for active fund managers who mostly focus on companies rather than economic and sector trends.

    By David Ashworth
  • uploads///part  copper production
    Macroeconomic Analysis

    World Refined Copper Production Rose 5% in 1Q15

    Refined copper production in China rose 9% YoY until March. China was the biggest contributor to the surge in refined copper production.

    By Mohit Oberoi, CFA
  • uploads///pharma challenges Japan
    Company & Industry Overviews

    What Are the Challenges for the Pharmaceutical Industry in Japan?

    Japan is the second-largest individual pharmaceutical market in the world. It accounts for less than 10% of the total global pharma market.

    By Jillian Dabney
  • uploads///holdings in valeant
    Company & Industry Overviews

    What Does Valeant’s Institutional Ownership Look Like?

    Of its total outstanding shares, Valeant Pharmaceuticals’ (VRX) institutional ownership stood at 69.2%.

    By Jillian Dabney
  • uploads///Diversification
    Macroeconomic Analysis

    Are You Thinking about Diversifying Your Portfolio?

    Geographical diversification allows your portfolio to keep earning returns in case your primary geography has not been doing well.

    By David Ashworth
  • uploads///negative interest rates
    Financials

    Will the Fed Have to Use More Unconventional Measures?

    Global monetary policy is unconventional. From an era of lowering interest rates to boost economic growth, central bankers are taking rates into negative territory.

    By Surbhi Jain
  • uploads///the new normal
    Financials

    Bill Gross’s Views on Growth and Inflation

    Gross believes that money has stopped generating growth and inflation. Equity prices are artificially elevated, and negative yields are guaranteeing capital losses.

    By Surbhi Jain
  • uploads///segemnts and margins
    Company & Industry Overviews

    Yes, There Will Be Margin Erosion for Valeant in 2017

    Of its three businesses, Bausch & Lomb’s share in Valeant Pharmaceuticals’ (VRX) overall EBITA (earnings before interest, tax, and amortization) was 32%.

    By Jillian Dabney
  • uploads///Spirits rising Market Share
    Company & Industry Overviews

    Distilled Spirits Are Growing Steadily

    Beer has been losing its market share in recent years, giving way to distilled spirits and wine.

    By Sirisha Bhogaraju
  • uploads///pharma division performance
    Earnings Report

    Sales Performance Analysis of Roche’s Pharmaceuticals Division

    Roche Holding (RHHBY) generated ~78% of its group sales from the pharmaceuticals division.

    By Jillian Dabney
  • uploads///IMFs Growth Projections January  Update
    Macroeconomic Analysis

    IMF expects economic growth to slow a bit, again

    The International Monetary Fund expects the world’s economic growth to rise by 3.5% in 2015 and 3.7% in 2016, a pace it describes as “moderate.”

    By David Ashworth
  • uploads///US Crude Oil Inventories Fell
    Macroeconomic Analysis

    US Crude Oil Inventories Fall Again: How Is Crude Oil Reacting?

    According to the U.S. Energy Information Administration’s report on June 29, 2016, US crude oil inventories fell by 4.1 MMbbls in the week ended June 24, 2016.

    By Sarah Sands
  • uploads///VRX
    Fund Managers

    Point72 Reduces Its Stake in Valeant Pharmaceuticals

    Point72 reduced its stake in Valeant Pharmaceuticals by selling 924,400 shares. It held 132,300 Valeant shares. Valeant accounted for 0.13% of the fund’s 4Q14 portfolio.

    By Diana Key
  • uploads///effect on GDP
    Financials

    How Brexit Could Impact GDP, Capital Flows, and Growth in the UK

    According to the International Monetary Fund’s World Economic Outlook Database, the UK’s GDP was $2.7 trillion in 2015.

    By Surbhi Jain
  • uploads///PArt  BEP
    Company & Industry Overviews

    Brookfield Renewable Energy: Biggest Yieldco by Asset Base

    With over 6,700 MW of hydro and wind capacity under operation, Brookfield Renewable Energy Partners (BEP) dwarfs all other yieldcos we’ve looked at.

    By Mike Sonnenberg
  • uploads///Chart  NVO
    Miscellaneous

    Performance of Novo Nordisk Stock in 2Q17

    Novo Nordisk (NVO) stock has risen ~18.6% in 2Q17. It has risen ~16.9% year-to-date as of July 7, 2017.

    By Mike Benson
  • uploads///BUD US Volumes
    Earnings Report

    Anheuser-Busch InBev Continues to Face Headwinds in the US

    In June 2015, Anheuser-Busch InBev announced an investment of over $1.5 billion toward product development and sustainability efforts in the US.

    By Sirisha Bhogaraju
  • uploads///US Producer Price Index Fell in March
    Macroeconomic Analysis

    US Producer Price Index Fell: Difficult Path ahead for the Fed

    On April 13, the U.S. Department of Labor declared that its producer price index fell 0.1% in March—compared to a 0.2% drop in February.

    By Sarah Sands
  • uploads///VIX
    Financials

    Can Increased Volatility Lead to More Capital Investment?

    The US stock market is currently subject to increased volatility. The past two years have seen market uncertainty heightening.

    By Surbhi Jain
  • uploads///part
    Macroeconomic Analysis

    Can Central Banks Fend Off the Next Recession?

    The interest rates are much lower compared to the levels in 2007 before the global recession. The federal funds rate is less than half the level in 2007.

    By Mohit Oberoi, CFA
  • uploads///EEM
    Healthcare

    What US Investors Need to Know about Emerging Market Risks

    According to the Institute of International Finance, the portfolio flows into emerging markets (EEM) slowed to $2.2 billion in August from $13.7 billion in July.

    By Anuradha Garg
  • uploads///Chart
    Company & Industry Overviews

    What Analysts Expect for AstraZeneca Going Forward

    AstraZeneca surpassed Wall Street analysts’ estimates for EPS and revenues and reported EPS of $2.37 on revenues of ~$22.4 billion during 2017.

    By Mike Benson
  • uploads/// Global growth
    Miscellaneous

    Why Investors Should Monitor Geopolitical Risks

    Localized geopolitical risks like the tension in the Middle East are unlikely to cause substantial damage to the markets in the long run, though they could bolster oil prices in the short term.

    By Peter Barnes
  • uploads///VRX analysts reco
    Company & Industry Overviews

    Valeant Pharmaceuticals on the Street: Analyst Ratings This February

    Of the seven analysts covering Valeant Pharmaceuticals in February 2018, two analysts have given the stock a “buy” or higher rating.

    By Kenneth Smith
  • uploads///
    Macroeconomic Analysis

    What’s behind the Stock Market Fall?

    A fall of more than 10% in market value from the most recent peak is generally considered to be a correction. The US indexes have had four such corrections since the onset of the current bull market cycle in 2009.

    By Ricky Cove
  • uploads///Chart
    Earnings Report

    AstraZeneca: Analyst Ratings and Recommendations

    As of January 31, 2018, AstraZeneca is trading at a forward PE (price-to-earnings) multiple of 21.5x, compared to the industry average of 14.8x.

    By Mike Benson
  • uploads///Graph
    Company & Industry Overviews

    Meningitis Vaccines Portfolio Could Boost GSK’s Revenues in 2018

    In 3Q17, GlaxoSmithKline (GSK) reported revenues close to 298 million pounds from the sale of its meningitis vaccines.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    GlaxoSmithKline Is Focused on Maintaining Leadership in This Segment

    To maintain its leadership in the chronic obstructive pulmonary disease (or COPD) segment, GlaxoSmithKline (GSK) has focused on shifting patients away from LAMA monotherapy to its LAMA/LABA bronchodilators.

    By Margaret Patrick
  • uploads///Cosentyx
    Company & Industry Overviews

    How Is Novartis’s Cosentyx Positioned for 2018?

    In 1Q17, 2Q17, and 3Q17, Novartis’s (NVS) Cosentyx generated revenues of $410 million, $490 million, and $556 million, respectively.

    By Daniel Collins
  • uploads///Alecensa
    Company & Industry Overviews

    Approval of Alecensa in Europe Could Boost Roche’s Revenue Growth

    In 1Q17, 2Q17, and 3Q17, Roche’s Alecensa reported revenues of 68 million Swiss francs, 80 million Swiss francs, and 96 million Swiss francs, respectively.

    By Daniel Collins
  • uploads///expected  generic launches
    Company & Industry Overviews

    TEVA Stock Price Rises on Generic Launch of Viread

    On December 15, 2017, Teva Pharmaceuticals (TEVA) announced the exclusive launch of the generic version of 300 mg Viread tablets in the United States.

    By Sarah Collins
  • uploads///Tecentriq
    Company & Industry Overviews

    What to Expect from Roche’s Tecentriq and Avastin in 2018

    In 1Q17, 2Q17, and 3Q17, Roche’s (RHHBY) Avastin generated revenues of 1.68 billion Swiss francs, 1.7 billion Swiss francs, and 1.6 billion Swiss francs, respectively.

    By Daniel Collins
  • uploads///Modern Insulin
    Company & Industry Overviews

    How Did Novo Nordisk’s Modern Insulin Segment Perform in 3Q17?

    In 3Q17, Novo Nordisk’s (NVO) NovoRapid reported revenues of 5.0 billion Danish krone (or DKK), which reflected ~9% growth on year-over-year (or YoY) basis.

    By Daniel Collins
  • uploads///Respiratory drugs
    Company & Industry Overviews

    How Teva’s Respiratory and Oncology Portfolios Are Positioned after 3Q17

    Teva’s Respiratory segment reported 3Q17 revenues of $351 million, which was ~30% higher YoY (year-over-year) and ~9% higher QoQ (quarter-over-quarter).

    By Daniel Collins
  • uploads///Cosentyx
    Company & Industry Overviews

    How Novartis’s Cosentyx Is Positioned after 3Q17

    In 3Q17, Novartis’s Cosentyx generated revenues of $556 million, which reflected a whopping 85% growth YoY (year-over-year) and ~13% growth QoQ.

    By Daniel Collins
  • uploads///part  ebitda
    Basic Materials

    ArcelorMittal’s 3Q17 Earnings: The Word on Wall Street

    According to the consensus estimates compiled by Thomson Reuters, ArcelorMittal is expected to post adjusted EBITDA of $1.9 billion in 3Q17.

    By Mohit Oberoi, CFA
  • uploads///Chart  NVO
    Miscellaneous

    Novo Nordisk Stock: Performance in 3Q17

    Novo Nordisk stock has risen ~12.3% in 3Q17. It has risen ~41.3% year-to-date as of October 20, 2017.

    By Mike Benson
  • uploads///Tafinlar Mekinist
    Company & Industry Overviews

    An Update on Novartis’s Tafinlar and Mekinist post 1H17

    In 1H17, Novartis’s (NVS) Tafinlar & Mekinist reported revenues of around $403 million, which reflected ~25% growth on a year-over-year (or YoY) basis.

    By Daniel Collins
  • uploads///Chart  HIV
    Company & Industry Overviews

    GlaxoSmithKline’s HIV Business in 2Q17

    ViiV Healthcare is a global specialist company in HIV medicines. It focuses on developing and delivering advanced treatments for patients with HIV.

    By Mike Benson
  • uploads///Chart  Alcon
    Company & Industry Overviews

    How Novartis’s Alcon Eye Care Business Performed in 2Q17

    Alcon reported revenues of $1.52 billion for 2Q17, which was 1% higher YoY (year-over-year) than the $1.51 billion we saw in 2Q16.

    By Mike Benson
  • uploads///Graph
    Company & Industry Overviews

    Fresenius Medical Care’s Net Profit Margins Could Fall Slightly

    For fiscal 2017, Wall Street analysts have projected Fresenius Medical Care’s net profit margins to be close to 6.2%, which is a YoY decline of ~70 basis points.

    By Margaret Patrick
  • uploads///Chart  Vaccines
    Earnings Report

    GlaxoSmithKline’s 2Q17 Earnings: Vaccines Business

    GSK’s Vaccines business reported 16.0% growth to ~1.1 billion pounds in 2Q17, including 5.0% growth at constant exchange rates and 11.0% positive impact of foreign exchange.

    By Mike Benson
  • uploads///Graph
    Company & Industry Overviews

    Farxiga Expected to Drive AstraZeneca’s Performance in Diabetes Segment

    In 1Q17, AstraZeneca’s leading sodium-glucose co-transporter 2 (or SGLT2) therapy for type-2 diabetes, Farxiga, reported revenues close to $270 million. This represents YoY growth of ~25% on a constant currency basis.

    By Margaret Patrick
  • Macroeconomic Analysis

    What Japan’s Manufacturing Suggests for Its Economy

    Japan’s manufacturing PMI (purchasing managers’ index) stood at 52.4 in June 2017 compared to 53.1 in May.

    By Sarah Sands
  • uploads///Japans Manufacturing PMI in May
    Macroeconomic Analysis

    Japan’s Manufacturing PMI in May, and What to Make of It

    The Japan Manufacturing PMI stood at 53.1 in May 2017, as compared to 52.7 in April, outperforming the preliminary market estimation of 52.0.

    By Sarah Sands
  • uploads///Leverage
    Company & Industry Overviews

    Has Shell’s Leverage Trend Reversed?

    Royal Dutch Shell’s (RDS.A) net debt-to-adjusted EBITDA ratio rose from 0.60x in 1Q15 to 1.9x in 1Q17.

    By Maitali Ramkumar
  • uploads///Chart  EPS
    Company & Industry Overviews

    How GlaxoSmithKline’s Valuation Changed after 1Q17

    GlaxoSmithKline is trading at a forward PE multiple of 15.4x, which is lower than the industry average of 16.4x as of May 31, 2017.

    By Mike Benson
  • uploads///unemp rate
    Macroeconomic Analysis

    How the Economy and Markets Could React to Tax Reforms

    The US Fed has gradually increased interest rates without spooking the fixed income markets and continues to project future hikes.

    By Ricky Cove
  • uploads///Graph
    Company & Industry Overviews

    Investigational Breast Cancer Drug Could Boost Novartis’s Position

    Novartis (NVS) has been striving to differentiate its investigational oncology drug, LEE011, from other breast cancer drugs in three areas.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Will Novartis’s Alcon Business See Growth in 2017?

    Novartis (NVS) expects its Alcon business to report low-single-digit revenue growth in 2017.

    By Margaret Patrick
  • uploads///Chinas Industrial Production in February
    Macroeconomic Analysis

    Will China’s Improved Industrial Production Impact Manufacturing?

    According to the National Bureau of Statistics of China, on a year-over-year (or YoY) basis, the country’s industrial production rose 6.3% in February 2017.

    By Sarah Sands
  • uploads///Decade of Low Interest Rate Across the Developed Markets
    Company & Industry Overviews

    Do Low Interest Rates Inflate Asset Prices?

    On January 26, financial adviser Andy Chase told CNBC’s Mike Santoli that equity valuations are at an all-time low. Chase believes that stocks provide the strongest investment opportunity in 2017.

    By Mary Sadler
  • uploads///Gold Price change
    Macroeconomic Analysis

    Bull Market: Expected for Gold, Not for Bonds

    Long-Term Outlook Remains Positive for Gold Bull Market Our view on the long-term gold price is unchanged. We see the recent weakness as a consolidation phase within what we believe is the early stages of the next bull market for gold. We continue to believe dislocations created by the unconventional policies being implemented by central […]

    By VanEck
  • uploads///Gold Price change
    Macroeconomic Analysis

    Bull Market: Expected for Gold but Not for Bonds

    Long-Term Outlook Remains Positive for Gold Bull Market Our view on the long-term gold price is unchanged. We see the recent weakness as a consolidation phase within what we believe is the early stages of the next bull market for gold. We continue to believe dislocations created by the unconventional policies being implemented by central […]

    By VanEck
  • uploads///Canadas Manufacturing PMI in October
    Macroeconomic Analysis

    Why Did Canada’s Manufacturing PMI Improve in October?

    Canada’s manufacturing PMI (purchasing managers’ index) stood at 51.1 in October 2016, as compared to 50.3 in September, and met the market estimate of 51.

    By Sarah Sands
  • uploads///Targets
    Company & Industry Overviews

    Analysts’ Ratings for PBR: Most Say ‘Hold’

    A survey of analysts shows that seven out of 11 companies have rated Petrobras (PBR) as a “hold,” a “neutral,” or a “market perform.”

    By Maitali Ramkumar
  • uploads///G GPS versus Consensus
    Macroeconomic Analysis

    Will BlackRock’s GPS Tool Give a Better GDP Outlook?

    Traditionally, a country’s GDP provides a measure of the monetary value of the goods and services it produces in a specific year.

    By Richard Turnill
  • uploads///Graph
    Company & Industry Overviews

    Will Novo Nordisk’s Core Capabilities Be Enough to Differentiate Its Research Pipeline?

    Novo Nordisk’s search for new molecules through partnerships and other alliances has proven instrumental in strengthening its R&D pipeline.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    What Will Drive Novo Nordisk’s Growth in Diabetes and Hemophilia?

    Novo Nordisk is exploring semaglutides and oral semaglutides for diabetes, N8-GP for hemophilia, and Somapacitan for growth disorders.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Teva’s Research Pipeline and Generic Product Launches in 2016

    The combined Teva Pharmaceutical–Allergan Generics company filed 65 ANDAs (Abbreviated New Drug Applications) in 2015.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Why Novo Nordisk Expects Double-Digit Growth in Diabetes Care in 2016

    Rising sales volumes, a focus on market share, and a switch to drugs that offer higher value will be the key growth drivers for NVO’s Diabetes Care segment.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Teva’s Generic Business and Its Transformation in Europe

    Despite its large size and large scope of operations, Teva Pharmaceutical’s European generics business has risen in operating profit margins by about 1,000 basis points.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Teva Pharmaceutical Still Dominates the Generic Market in Europe

    With a share of about 14%, Teva Pharmaceutical Industries (TEVA) is currently the top-ranking player in the European generic pharmaceutical market.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Teva’s OTC Business Is Playing out to Be a Key Growth Driver

    In addition to its generic pharmaceutical business, Teva Pharmaceutical also has a significant presence in the major categories of the OTC drug business.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Teva’s Asthma Segment: What Could Boost Its Revenues in 2016?

    On March 23, 2016, the FDA approved Cinqair (reslizumab) as a maintenance therapy for patients with severe asthma.

    By Margaret Patrick
  • uploads///anr
    Earnings Report

    Analyst Recommendations for Roche: Buy, Hold, or Sell?

    After the earnings results, analysts updated Roche’s consensus 12-month target price to $36.85 from the $37.2 pre-earnings price.

    By Jillian Dabney
  • uploads///Chart
    Earnings Report

    GSK’s Novartis Acquisition Key to Growth in Its Vaccines Segment

    GSK expects the revenues of its Vaccines segment to grow with the addition of meningitis vaccines from Novartis and the growing demand in European markets.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    GSK’s HIV Products Expected to Have Driven 2Q Earnings

    GlaxoSmithKline is set to release its 2Q16 earnings on July 27, 2016. Analysts estimate EPS (earnings per share) of 0.42 British pounds for 2Q16.

    By Mike Benson
  • uploads///ANR
    Earnings Report

    How Much Upward Potential Does Roche Really Have?

    Out of four brokerage firms surveyed by Bloomberg on July 14, 2016, three rated Roche as a “buy,” while one rated the company as a “hold.”

    By Jillian Dabney
  • uploads///Volatility Spiked at the Major Events
    Fund Managers

    Market Uncertainty to Remain: Where Do the Markets Go Next?

    After the Brexit vote, Market volatility has increased. Although the Markets have recovered their losses, it’s still a warning sign for the global economy.

    By Sarah Sands
  • uploads///Ext
    Miscellaneous

    What Has Impacted the Global Financial Markets in 2016?

    Apart from crude oil prices, it was China (FXI) (YINN) whose shaky economic fundamentals resulted in panic in global financial markets.

    By David Ashworth
  • uploads///Ophthal eye care
    Company & Industry Overviews

    Valeant’ Eye Health and Consumer-Oriented Portfolios

    Valeant’s eye health products serve a wide range of eye disorders such as glaucoma, eye allergies, conjunctivitis, dry eye, and retinal diseases.

    By Jillian Dabney
  • uploads///Falling Unemployment Rate in the Eurozone
    Fund Managers

    Alexander Dryden Explains Why Europe Has More Room to Run

    According to Dryden, the falling unemployment rate and improving consumer spending in Europe are important factors that will change the outlook of the economy.

    By Sarah Sands
  • uploads///global brands
    Company & Industry Overviews

    What Happened in the Valeant-Philidor Controversy?

    Valeant’s (VRX) controversies started with Philidor, a specialty pharmacy company that was accused of altering doctor’s prescriptions so it could sell more of Valeant’s costly drugs.

    By Jillian Dabney
  • uploads///A China GDP
    Company & Industry Overviews

    Are Indicators Suggesting an Economic Turnaround?

    Over the past few years, China’s economic growth witnessed a significant slowdown. In the first quarter, the economy fell to 6.7%.

    By Aberdeen Closed-End Funds
  • uploads///Performance of Barclay Hedge Fund Index versus CTA Index
    Macroeconomic Analysis

    Hedge Funds Outperformed in April: Are Trends Breaking?

    In April 2016, hedge funds outperformed the CTA index. Worldwide, central banks’ dovish policy stances helped the funds to provide such returns.

    By Sarah Sands
  • uploads///Annotated
    Earnings Report

    Behind Eni’s Stock Performance after 1Q16

    Eni SpA (E) announced its 1Q16 earnings on April 29, 2016. On the same day, Eni opened at $32.7, marginally higher than the previous day’s close of $32.6.

    By Maitali Ramkumar
  • uploads///Chart
    Earnings Report

    How Did GSK’s Other Global Pharmaceuticals Franchises Perform?

    The global pharmaceuticals business of GlaxoSmithKline (GSK) includes various products like respiratory, cardiovascular, metabolic and urology, immuno-inflammation, and established products.

    By Mike Benson
  • uploads///deleveraging
    Fund Managers

    4 Ways an Economy Can Deleverage: Ray Dalio Explains

    In his “Economic Principles at Work” template, Ray Dalio identifies four ways any world (ACWI)(VTI)(VEU) economy can deleverage. Find out why this matters.

    By Surbhi Jain
  • uploads///Graph
    Company & Industry Overviews

    How Could Generic Competition Affect Copaxone’s Revenues in 2016?

    Wall Street analysts have projected that Teva Pharmaceutical Industries (TEVA) will earn about $3.5 billion in revenues from Copaxone sales in 2016

    By Margaret Patrick
  • uploads///mnfg pmi
    Macroeconomic Analysis

    Can China’s New Growth Drivers Wake the Dragon?

    The Chinese economy has been receding, and China saw its double-digit growth rates, recorded after the 2009 economic recession, fall to less than 7%.

    By Surbhi Jain
  • uploads///eeeeabfcfcdadaef
    Macroeconomic Analysis

    In Case You Haven’t Noticed, China’s Growth Drivers Are Changing!

    A decade of manufacturing and export-fueled growth in China has gotten us quite accustomed to seeing China in that light. This needs to change.

    By Surbhi Jain
  • uploads///Perjeta and kadcyla
    Company & Industry Overviews

    Inside Roche’s Next Oncology Portfolio Drivers

    In 2015, Roche’s Perjeta and Kadcyla earned ~$1.41 billion and ~$0.81 billion, respectively. High sales drove Perjeta’s strong growth in the US and Europe.

    By Jillian Dabney
  • uploads///MAbthera
    Company & Industry Overviews

    Will Gazyva Be able to Replace Roche’s MabThera?

    During 2015, MabThera fetched about ~$7.1 billion for Roche Holding, proving itself to be the largest revenue contributor at ~14.6% of total revenue.

    By Jillian Dabney
  • uploads///fcau pm
    Company & Industry Overviews

    Fiat Chrysler Repays Term Loan, Followed by Moody’s Rating

    Fiat Chrysler Automobiles (FCAU) has a market cap of $9.7 billion. FCAU fell by 2.2% to close at $7.60 per share as of March 15, 2016.

    By Gabriel Kane
  • uploads///EV to EBITDA
    Company & Industry Overviews

    Decoding Roche’s Performance on EV-to-EBITDA Basis

    As of March 8, Roche Holding was trading at a forward EV-to-EBITDA multiple of 9.73x—a discount compared to Bristol-Myers Squibb’s 16.09x.

    By Jillian Dabney
  • uploads///fcau pm
    Company & Industry Overviews

    Fiat Chrysler Automobiles Sales Rose in February 2016

    Fiat Chrysler Automobiles (FCAU) has a market capitalization of $9.4 billion. FCAU rose by 7.2% to close at $7.34 per share as of March 1, 2016.

    By Gabriel Kane
  • uploads///Guidance for
    Earnings Report

    Expectations for Valeant Pharmaceuticals in 2016

    Valeant Pharmaceuticals (VRX) expects 2016 revenues to be $12.5–12.7 billion, up by 21%. In January 2016, the company launched its Valeant Access Program in partnership with Walgreens.

    By Jillian Dabney
  • uploads///TEVA acquisition financing Part
    Earnings Report

    How Will Teva Finance the Actavis Acquisition?

    Teva hopes to close the Actavis deal by the first quarter of 2016. Of the acquisition price of $40.5 billion, $6.8 billion will be in the form of equity, or 100.5 million shares of Teva.

    By Peter Neil
  • uploads///Graph
    Company & Industry Overviews

    Why Valeant Pharmaceuticals Lowered Its Guidance for 4Q15

    Valeant Pharmaceuticals (VRX) lowered its financial guidance for 4Q15 due to significant disruptions in the company’s business.

    By Margaret Patrick
  • uploads///Graph
    Miscellaneous

    Entresto: First-in-Class Angiotensin Receptor Neprilysin Inhibitor

    Entresto is the first-in-class angiotensin receptor neprilysin inhibitor therapy (or ARNI), which has been approved in the US and Europe.

    By Margaret Patrick
  • uploads///Graph
    Miscellaneous

    FDA Sets December 29 as Lesinurad’s PDUFA Date

    The FDA has scheduled the Prescription Drug User Fee Act (or PDUFA) date for AstraZeneca’s (AZN) lesinurad for December 29, 2015. Lesinurad is a drug indicated for gout.

    By Margaret Patrick
  • uploads///global nominal gdp
    Fund Managers

    Jeffrey Gundlach: Why Global GDP Growth Doesn’t Warrant a Rate Hike

    The “King of Bonds,” Jeffrey Gundlach, has a huge following in the investment community for his views about the US bond market (BND)(AGG) and the looming interest rate hike.

    By Surbhi Jain
  • uploads///Graph
    Miscellaneous

    The European Commission Approved Novartis’s Entresto

    On November 24, Novartis announced that the European Commission had approved Entresto as a therapy for adult patients suffering from symptomatic chronic heart failure with reduced ejection fraction.

    By Margaret Patrick
  • uploads///Utilization of devices
    Miscellaneous

    Why Has Alibaba Acquired Youku Tudou?

    On November 6, 2015, Bloomberg Business reported that Alibaba (BABA) agreed to buy Youku Tudou (YOKU) for a total of $4.8 billion.

    By Shirley Pelts
  • uploads///Ap
    Macroeconomic Analysis

    The World Economy Could Enter into the Cycle of Currency War

    International trade is dependent upon the exchange rate. If a country’s currency is depreciating, it should lead to a rise in exports and a fall in imports.

    By Sarah Sands
  • uploads///Graph
    Company & Industry Overviews

    Novo Nordisk Benefits from Strong Presence in Europe and China

    Novo Nordisk (NVO) generates 22.7% of its total revenues from the European market. It’s Novo Nordisk’s second largest market. China accounts for about 9.1% of the company’s total revenues.

    By Margaret Patrick
  • uploads///US LRB Market
    Company & Industry Overviews

    Nestle Continues to Dominate the US Bottled Water Industry

    Nestle Waters North America is the market leader of the US bottled water industry.

    By Sirisha Bhogaraju
  • uploads///key financials part
    Company & Industry Overviews

    An Investor’s Guide to Tesla Motors’s Key Financials

    Analysis of Tesla’s key financials shows that its revenues grew more than 15 times between FY 2011 and FY 2014.

    By Mohit Oberoi, CFA
  • uploads///china car sales
    Macroeconomic Analysis

    China’s Aluminum Demand Indicators Drift Lower

    In June, China’s passenger car sales fell 3.2% compared with last year—the first yearly decline since February 2013.

    By Mohit Oberoi, CFA
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.